Cancer Genetics, Inc. (CGIX)
(Delayed Data from NSDQ)
$0.22 USD
-0.01 (-3.17%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.23 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
[CGIX]
Reports for Purchase
Showing records 1 - 20 ( 65 total )
Industry: Medical Services
Termination of coverage due to resource reallocation
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical Services
ValuEngine Detailed Valuation Report for CGIX
Provider: ValuEngine, Inc
Industry: Medical Services
Oncomine Comprehensive Assay Next-Generation Version Introduced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical Services
NovellusDx Merger Announced; Potentially Transformative Transaction; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical Services
2Q18 Financial Results Reported; Top-Line Miss, Net Loss In-Line; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical Services
Recent Developments in Precision Medicine Bode Well; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical Services
1Q 2018 Financial Results Reported; Revenue Growth Lagging; Reducing Price Target to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical Services
Industry: Medical Services
Leadership Transition Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical Services
MODEL Please note: This model may be included in a separate report on the company issued by the broker on the same day.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Industry: Medical Services
Immuno-Oncology Panel Expansion Underscores Leadership; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical Services
Turning the Corner in 2018; Cash Replenished; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical Services
3Q17 Financial Results Reported; Looking Ahead to Profitability
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical Services
VivoPharm Acquisition, 25th I-O Contract - BUY
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Industry: Medical Services
Management Discussions Highlight Potential Future Strategic Directions; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical Services
2Q17 Financial Results Reported; Edging Towards Profitability; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Industry: Medical Services
We are initiating coverage with a BUY rating and 12-18 month price target of $11.00 per share
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Industry: Medical Services
1Q17 Financial Results Reported; Profitability Gradually Approaching; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Industry: Medical Services
1Q17 Financial Results Reported; Profitability Gradually Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Industry: Medical Services
Complete::IO? Immuno-Oncology Assay Validation Achieved; Reiterate Buy
Provider: Rodman & Renshaw, Co.